Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

Hao Yin,Wen Xue,Sidi Chen,Roman L Bogorad,Eric Benedetti,Markus Grompe,Victor Koteliansky,Phillip A Sharp,Tyler Jacks,Daniel G Anderson

DOI: https://doi.org/10.1038/nbt.2884

IF: 46.9

2014-03-30

Nature Biotechnology

Abstract:CRISPR-Cas9-mediated genome editing corrects a hereditary tyrosinemia disease mutation in the liver of adult mice.

biotechnology & applied microbiology

What problem does this paper attempt to address?

Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats

Yanjiao Shao,Liren Wang,Nana Guo,Shengfei Wang,Lei Yang,Yajing Li,Mingsong Wang,Shuming Yin,Honghui Han,Li Zeng,Ludi Zhang,Lijian Hui,Qiurong Ding,Jiqin Zhang,Hongquan Geng,Mingyao Liu,Dali Li

DOI: https://doi.org/10.1074/jbc.RA117.000347

2018-05-04

Abstract:Hereditary tyrosinemia type I (HTI) is a metabolic genetic disorder caused by mutation of fumarylacetoacetate hydrolase (FAH). Because of the accumulation of toxic metabolites, HTI causes severe liver cirrhosis, liver failure, and even hepatocellular carcinoma. HTI is an ideal model for gene therapy, and several strategies have been shown to ameliorate HTI symptoms in animal models. Although CRISPR/Cas9-mediated genome editing is able to correct the Fah mutation in mouse models, WT Cas9 induces numerous undesired mutations that have raised safety concerns for clinical applications. To develop a new method for gene correction with high fidelity, we generated a Fah mutant rat model to investigate whether Cas9 nickase (Cas9n)-mediated genome editing can efficiently correct the Fah First, we confirmed that Cas9n rarely induces indels in both on-target and off-target sites in cell lines. Using WT Cas9 as a positive control, we delivered Cas9n and the repair donor template/single guide (sg)RNA through adenoviral vectors into HTI rats. Analyses of the initial genome editing efficiency indicated that only WT Cas9 but not Cas9n causes indels at the on-target site in the liver tissue. After receiving either Cas9n or WT Cas9-mediated gene correction therapy, HTI rats gained weight steadily and survived. Fah-expressing hepatocytes occupied over 95% of the liver tissue 9 months after the treatment. Moreover, CRISPR/Cas9-mediated gene therapy prevented the progression of liver cirrhosis, a phenotype that could not be recapitulated in the HTI mouse model. These results strongly suggest that Cas9n-mediated genome editing is a valuable and safe gene therapy strategy for this genetic disease.
In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Huan Zhao,Yan Li,Lingjuan He,Wenjuan Pu,Wei Yu,Yi Li,Yan-Ting Wu,Chenming Xu,Yuda Wei,Qiurong Ding,Bao-Liang Song,Hefeng Huang,Bin Zhou

DOI: https://doi.org/10.1161/circulationaha.119.042476

IF: 37.8

2020-01-01

Circulation

Abstract:Background: Mutations in low-density lipoprotein (LDL) receptor (LDLR) are one of the main causes of familial hypercholesterolemia, which induces atherosclerosis and has a high lifetime risk of cardiovascular disease. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is an effective tool for gene editing to correct gene mutations and thus to ameliorate disease. Methods: The goal of this work was to determine whether in vivo somatic cell gene editing through the CRISPR/Cas9 system delivered by adeno-associated virus (AAV) could treat familial hypercholesterolemia caused by the Ldlr mutant in a mouse model. We generated a nonsense point mutation mouse line, Ldlr(E208X), based on a relevant familial hypercholesterolemia-related gene mutation. The AAV-CRISPR/Cas9 was designed to correct the point mutation in the Ldlr gene in hepatocytes and was delivered subcutaneously into Ldlr(E208X) mice. Results: We found that homogeneous Ldlr(E208X) mice (n=6) exhibited severe atherosclerotic phenotypes after a high-fat diet regimen and that the Ldlr mutation was corrected in a subset of hepatocytes after AAV-CRISPR/Cas9 treatment, with LDLR protein expression partially restored (n=6). Compared with the control groups (n=6 each group), the AAV-CRISPR/Cas9 with targeted single guide RNA group (n=6) had significant reductions in total cholesterol, total triglycerides, and LDL cholesterol in the serum, whereas the aorta had smaller atherosclerotic plaques and a lower degree of macrophage infiltration. Conclusions: Our work shows that in vivo AAV-CRISPR/Cas9-mediated Ldlr gene correction can partially rescue LDLR expression and effectively ameliorate atherosclerosis phenotypes in Ldlr mutants, providing a potential therapeutic approach for the treatment of patients with familial hypercholesterolemia.
In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1

Jean-François Rivest,Sophie Carter,Claudia Goupil,Pénélope Antérieux,Denis Cyr,Roth-Visal Ung,Dorothée Dal Soglio,Fabrice Mac-Way,Paula J Waters,Massimiliano Paganelli,Yannick Doyon

DOI: https://doi.org/10.1093/genetics/iyae139

IF: 4.402

2024-08-23

Genetics

Abstract:Hereditary tyrosinemia type 1 is an autosomal recessive disorder caused by mutations (pathogenic variants) in fumarylacetoacetate hydrolase, an enzyme involved in tyrosine degradation. Its loss results in the accumulation of toxic metabolites that mainly affect the liver and kidneys and can lead to severe liver disease and liver cancer. Tyrosinemia type 1 has a global prevalence of approximately 1 in 100,000 births but can reach up to 1 in 1,500 births in some regions of Québec, Canada. Mutating functionally related 'modifier' genes (i.e., genes that, when mutated, affect the phenotypic impacts of mutations in other genes) is an emerging strategy for treating human genetic diseases. In vivo somatic genome editing in animal models of these diseases is a powerful means to identify modifier genes and fuel treatment development. In this study, we demonstrate that mutating additional enzymes in the tyrosine catabolic pathway through liver-specific genome editing can relieve or worsen the phenotypic severity of a murine model of tyrosinemia type 1. Neonatal gene delivery using recombinant adeno-associated viral vectors expressing Staphylococcus aureus Cas9 under the control of a liver-specific promoter led to efficient gene disruption and metabolic rewiring of the pathway, with systemic effects that were distinct from the phenotypes observed in whole-body knockout models. Our work illustrates the value of using in vivo genome editing in model organisms to study the direct effects of combining pathological mutations with modifier gene mutations in isogenic settings.
CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I

Nan Li,Shixue Gou,Jiaowei Wang,Quanjun Zhang,Xingyun Huang,Jingke Xie,Li Li,Qin Jin,Zhen Ouyang,Fangbing Chen,Weikai Ge,Hui Shi,Yanhui Liang,Zhenpeng Zhuang,Xiaozhu Zhao,Meng Lian,Yinghua Ye,Longquan Quan,Han Wu,Liangxue Lai,Kepin Wang

DOI: https://doi.org/10.1016/j.ymthe.2020.11.023

IF: 12.91

2021-03-01

Molecular Therapy

Abstract:<p>Patients with hereditary tyrosinemia type I (HT1) present acute and irreversible liver and kidney damages during infancy. CRISPR/Cas9-mediated gene correction during infancy may provide a promising approach to treat patients with HT1. However, all previous studies were performed on adult HT1 rodent models, which cannot authentically recapitulate some symptoms of human patients. To translate precise gene therapy to clinical practice, the efficacy and safety should be verified in large animals. Here, we delivered CRISPR/Cas9 and donor templates via adeno-associated virus to newborn HT1 rabbits. The lethal phenotypes could be rescued, and notably, these HT1 rabbits reached adulthood normally without 2-(2-nitro-4-trifluoromethylbenzyol)-1,3 cyclohexanedione administration, and even gave birth to offspring. AAV-treated HT1 rabbits displayed normal liver and kidney structures and functions. Homology-directed repair-mediated precise gene corrections and non-homologous end joining-mediated out-of-frame to in-frame corrections in the livers were observed with efficiencies of 0.90%–3.71% and 2.39%–6.35%, respectively, which appeared to be sufficient to recover liver function and decrease liver and kidney damages. This study provides useful large-animal preclinical data for rescuing hepatocyte-related monogenetic metabolic disorders with precise gene therapy.</p>

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Hyewon Jang,Dong Hyun Jo,Chang Sik Cho,Jeong Hong Shin,Jung Hwa Seo,Goosang Yu,Ramu Gopalappa,Daesik Kim,Sung-Rae Cho,Jeong Hun Kim,Hyongbum Henry Kim

DOI: https://doi.org/10.1038/s41551-021-00788-9

IF: 28.1

2021-08-26

Nature Biomedical Engineering

Abstract:The use of prime editing—a gene-editing technique that induces small genetic changes without the need for donor DNA and without causing double strand breaks—to correct pathogenic mutations and phenotypes needs to be tested in animal models of human genetic diseases. Here we report the use of prime editors 2 and 3, delivered by hydrodynamic injection, in mice with the genetic liver disease hereditary tyrosinemia, and of prime editor 2, delivered by an adeno-associated virus vector, in mice with the genetic eye disease Leber congenital amaurosis. For each pathogenic mutation, we identified an optimal prime-editing guide RNA by using cells transduced with lentiviral libraries of guide-RNA-encoding sequences paired with the corresponding target sequences. The prime editors precisely corrected the disease-causing mutations and led to the amelioration of the disease phenotypes in the mice, without detectable off-target edits. Prime editing should be tested further in more animal models of genetic diseases.

engineering, biomedical
CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

Cong Huai,Chenqiang Jia,Ruilin Sun,Peipei Xu,Taishan Min,Qihan Wang,Chengde Zheng,Hongyan Chen,Daru Lu

DOI: https://doi.org/10.1007/s00439-017-1801-z

2017-01-01

Human Genetics

Abstract:Hemophilia B (HB) is an X-linked disorder caused by defects of F9 encoded coagulation factor IX, which is an ideal model for gene therapy. Most existing HB gene therapies are based on viral mediated gene supplementation, which could increase immunoreaction. In this study, CRISPR/Cas9 system was used for gene correction in an F9 mutant HB mouse model in both adult mice (in vivo) and in germline cells (ex vivo). In vivo, naked Cas9-sgRNA plasmid and donor DNA were delivered to HB mice livers to recover the mutation via hydrodynamic tail vein (HTV) injection. 62.5% of the HTV-treated mice showed a detectable gene correction (>1%) in the F9 alleles of hepatocytes, which was sufficient to remit the coagulation deficiency. Ex vivo, three different forms of Cas9 were microinjected into germline cells of HB mice to investigate their efficiency and safety in gene correction. Cas9 protein showed higher gene recovery rates, less embryo toxicity, and lower mosaic repair percentage, making it more suitable for germline gene therapy. Our study strongly supports that CRISPR/Cas9-mediated genome editing is feasible in gene therapy of genetic disorders.
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1

Ilayda Ates,Callie Stuart,Tanner Rathbone,Mercedes Barzi,Gordon He,Angela M. Major,Vijay Shankar,Rachel A. Lyman,Sidney S. Angner,Trudy F.C. Mackay,Shanthi Srinivasan,Alton Brad Farris,Karl-Dimiter Bissig,Renee N. Cottle

DOI: https://doi.org/10.1097/hc9.0000000000000424

2024-04-26

Hepatology Communications

Abstract:Background: We previously demonstrated the successful use of in vivo CRISPR gene editing to delete 4-hydroxyphenylpyruvate dioxygenase ( HPD ) to rescue mice deficient in fumarylacetoacetate hydrolase (FAH), a disorder known as hereditary tyrosinemia type 1 (HT1). The aim of this study was to develop an ex vivo gene-editing protocol and apply it as a cell therapy for HT1. Methods: We isolated hepatocytes from wild-type (C57BL/6J) and Fah −/− mice and then used an optimized electroporation protocol to deliver Hpd -targeting CRISPR-Cas9 ribonucleoproteins into hepatocytes. Next, hepatocytes were transiently incubated in cytokine recovery media formulated to block apoptosis, followed by splenic injection into recipient Fah −/− mice. Results: We observed robust engraftment and expansion of transplanted gene-edited hepatocytes from wild-type donors in the livers of recipient mice when transient incubation with our cytokine recovery media was used after electroporation and negligible engraftment without the media (mean: 46.8% and 0.83%, respectively; p =0.0025). Thus, the cytokine recovery medium was critical to our electroporation protocol. When hepatocytes from Fah −/− mice were used as donors for transplantation, we observed 35% and 28% engraftment for Hpd -Cas9 ribonucleoproteins and Cas9 mRNA, respectively. Tyrosine, phenylalanine, and biochemical markers of liver injury normalized in both Hpd -targeting Cas9 ribonucleoprotein and mRNA groups independent of induced inhibition of Hpd through nitisinone, indicating correction of disease indicators in Fah −/− mice. Conclusions: The successful liver cell therapy for HT1 validates our protocol and, despite the known growth advantage of HT1, showcases ex vivo gene editing using electroporation in combination with liver cell therapy to cure a disease model. These advancements underscore the potential impacts of electroporation combined with transplantation as a cell therapy.

gastroenterology & hepatology
CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis

Dong Hyun Jo,Dong Woo Song,Chang Sik Cho,Un Gi Kim,Kyu Jun Lee,Kihwang Lee,Sung Wook Park,Daesik Kim,Jin Hyoung Kim,Jin-Soo Kim,Seokjoong Kim,Jeong Hun Kim,Jung Min Lee

DOI: https://doi.org/10.1126/sciadv.aax1210

IF: 13.6

2019-10-04

Science Advances

Abstract:Therapeutic genome editing of a nonsense mutation showed functional gain in a mouse model of inherited retinal degeneration.

multidisciplinary sciences
Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

Dan Lu,Xiuli Gong,Xinbing Guo,Qin Cai,Yanwen Chen,Yiwen Zhu,Xiao Sang,Hua Yang,Miao Xu,Yitao Zeng,Dali Li,Fanyi Zeng

DOI: https://doi.org/10.1089/hum.2023.202

Abstract:β654-thalassemia is caused by a point mutation in the second intron (IVS-II) of the β-globin gene that activates a cryptic 3' splice site, leading to incorrect RNA splicing. Our previous study demonstrated that when direct deletion of the β654 mutation sequence or the cryptic 3' splice site in the IVS-II occurs, correct splicing of β-globin mRNA can be restored. Herein, we conducted an in-depth analysis to explore a more precise gene-editing method for treating β654-thalassemia. A single-base substitution of the cryptic 3' acceptor splice site was introduced in the genome of a β654-thalassemia mouse model using clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9(Cas9)-mediated homology-directed repair (HDR). All of the HDR-edited mice allow the detection of correctly spliced β-globin mRNA. Pathological changes were improved compared with the nonedited β654 mice. This resulted in a more than twofold increase in the survival rate beyond the weaning age of the mice carrying the β654 allele. The therapeutic effects of this gene-editing strategy showed that the typical β-thalassemia phenotype can be improved in a dose-dependent manner when the frequency of HDR is over 20%. Our research provides a unique and effective method for correcting the splicing defect by gene editing the reactive splicing acceptor site in a β654 mouse model.
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Daniel Reichart,Gregory A. Newby,Hiroko Wakimoto,Mingyue Lun,Joshua M. Gorham,Justin J. Curran,Aditya Raguram,Daniel M. DeLaughter,David A. Conner,Júlia D. C. Marsiglia,Sajeev Kohli,Lukas Chmatal,David C. Page,Nerea Zabaleta,Luk Vandenberghe,David R. Liu,Jonathan G. Seidman,Christine Seidman

DOI: https://doi.org/10.1038/s41591-022-02190-7

IF: 82.9

2023-02-17

Nature Medicine

Abstract:Dominant missense pathogenic variants in cardiac myosin heavy chain cause hypertrophic cardiomyopathy (HCM), a currently incurable disorder that increases risk for stroke, heart failure and sudden cardiac death. In this study, we assessed two different genetic therapies—an adenine base editor (ABE8e) and a potent Cas9 nuclease delivered by AAV9—to prevent disease in mice carrying the heterozygous HCM pathogenic variant myosin R403Q. One dose of dual-AAV9 vectors, each carrying one half of RNA-guided ABE8e, corrected the pathogenic variant in ≥70% of ventricular cardiomyocytes and maintained durable, normal cardiac structure and function. An additional dose provided more editing in the atria but also increased bystander editing. AAV9 delivery of RNA-guided Cas9 nuclease effectively inactivated the pathogenic allele, albeit with dose-dependent toxicities, necessitating a narrow therapeutic window to maintain health. These preclinical studies demonstrate considerable potential for single-dose genetic therapies to correct or silence pathogenic variants and prevent the development of HCM.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Haokun Zhang,Ruilin Sun,Jian Fei,Hongyan Chen,Daru Lu

DOI: https://doi.org/10.3390/ijms23115948

2022-05-25

Abstract:Prime editing was used to insert and correct various pathogenic mutations except for beta-thalassemia variants, which disrupt functional beta-globin and prevent hemoglobin assembly in erythrocytes. This study investigated the effect of gene correction using prime editor version 3 (PE3) in a mouse model with the human beta-thalassemia IVS-II-654 mutation (C > T). The T conversion generates a 5′ donor site at intron 2 of the beta-globin gene resulting in aberrant splicing of pre-mRNA, which affects beta-globin expression. We microinjected PE3 components (pegRNA, nick sgRNA, and PE2 mRNA) into the zygotes from IVS-II-654 mice to generate mutation-edited mice. Genome sequencing of the IVS-II-654 site showed that PE3 installed the correction (T > C), with an editing efficiency of 14.29%. Reverse transcription-PCR analysis showed that the PE3-induced conversion restored normal splicing of beta-globin mRNA. Subsequent comprehensive phenotypic analysis of thalassemia symptoms, including anemic hematological parameters, anisocytosis, splenomegaly, cardiac hypertrophy, extramedullary hematopoiesis, and iron overload, showed that the corrected IVS-II-654 mice had a normal phenotype identical to the wild type mice. Off-target analysis of pegRNA and nick sgRNA additionally showed the genomic safety of PE3. These results suggest that correction of beta-thalassemia mutation by PE3 may be a straightforward therapeutic strategy for this disease.
In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency

Chun-Qing Song,Dan Wang,Tingting Jiang,Kevin O'Connor,Qiushi Tang,Lingling Cai,Xiangrui Li,Zhiping Weng,Hao Yin,Guangping Gao,Christian Mueller,Terence R Flotte,Wen Xue

DOI: https://doi.org/10.1089/hum.2017.225

Abstract:CRISPR (clustered regularly interspaced short palindromic repeats) genome editing holds promise in the treatment of genetic diseases that currently lack effective long-term therapies. Patients with alpha-1 antitrypsin (AAT) deficiency develop progressive lung disease due to the loss of AAT's antiprotease function and liver disease due to a toxic gain of function of the common mutant allele. However, it remains unknown whether CRISPR-mediated AAT correction in the liver, where AAT is primarily expressed, can correct either or both defects. Here we show that AAV delivery of CRISPR can effectively correct Z-AAT mutation in the liver of a transgenic mouse model. Specifically, we co-injected two AAVs: one expressing Cas9 and another encoding an AAT guide RNA and homology-directed repair template. In both neonatal and adult mice, this treatment partially restored M-AAT in the serum. Furthermore, deep sequencing confirmed both indel mutations and precise gene correction in the liver, permitting careful analysis of gene editing events in vivo. This study demonstrates a proof of concept for the application of CRISPR-Cas9 technology to correct AAT mutations in vivo and validates continued exploration of this approach for the treatment of patients with AAT deficiency.
Development and application of CRISPR/Cas9 technologies in genomic editing.

Cui Zhang,Renfu Quan,Jinfu Wang

DOI: https://doi.org/10.1093/hmg/ddy120

IF: 5.1214

2018-01-01

Human Molecular Genetics

Abstract:Genomic editing to correct disease-causing mutations is a promising approach for the treatment of human diseases. As a simple and programmable nuclease-based genomic editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has substantially improved the ability to make precise changes in the human genome. Rapid development of CRISPR-based technologies in recent years has expanded its application scope and promoted CRISPR-based therapies in preclinical trails. Here, we review the application of the CRISPR system over the last 2 years; including its development and application in base editing, transcription modulation and epigenetic editing, genomic-scale screening, and cell and embryo therapy. Finally, the prospects and challenges related to application of CRISPR/Cas9 technologies are discussed.
In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa

Benjamin Bakondi,Wenjian Lv,Bin Lu,Melissa K Jones,Yuchun Tsai,Kevin J Kim,Rachelle Levy,Aslam Abbasi Akhtar,Joshua J Breunig,Clive N Svendsen,Shaomei Wang

DOI: https://doi.org/10.1038/mt.2015.220

IF: 12.91

2016-03-01

Molecular Therapy

Abstract:Reliable genome editing via Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 may provide a means to correct inherited diseases in patients. As proof of principle, we show that CRISPR/Cas9 can be used in vivo to selectively ablate the rhodopsin gene carrying the dominant S334ter mutation (Rho(S334)) in rats that model severe autosomal dominant retinitis pigmentosa. A single subretinal injection of guide RNA/Cas9 plasmid in combination with electroporation generated allele-specific disruption of Rho(S334), which prevented retinal degeneration and improved visual function.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Shuhong Ma,Wenjian Jiang,Xujie Liu,Wen-Jing Lu,Tao Qi,Jingjing Wei,Fujian Wu,Yun Chang,Siyao Zhang,Yabing Song,Rui Bai,Jianbing Wang,Andrew S Lee,Hongjia Zhang,Yongming Wang,Feng Lan,Jianbin Wang,Andrew Lee

DOI: https://doi.org/10.1161/circresaha.120.318674

IF: 23.213

2021-09-17

Circulation Research

Abstract:Rationale: Genetic editing has shown great potential for the treatment of human hereditary disorders via the elimination of mutations in embryos. However, the efficiency and safety of germline gene editing are not well understood. Objective: We aimed to examine the preclinical efficacy/safety of embryonic base editing in a mouse model of hypertrophic cardiomyopathy (HCM) using a novel adenine base editor (ABE) platform. Methods and Results: Here, we described the use of an ABEmax-NG to directly correct the pathogenic R404Q/+ mutation (Myh6 c.1211C>T) in embryos for a mouse model of HCM, increasing the number of wild-type embryos for in vitro fertilization. Delivery of the ABEmax-NG mRNA to embryos from R404Q/+ HCM mice resulted in 62.5-70.8% correction of the Myh6 c.1211C>T, reducing the level of mutant RNA and eliminating HCM in the post-natal mice as well as their offspring. In addition, the same sgRNA was also used to target an intronic locus (TGG PAM) with an overall editing rate of 86.7%, thus confirming that ABEmax-NG can efficiently edit target loci with different PAMs (NG) and genomic distribution in vivo. Compared with CRISPR/ssODN-mediated correction, ABEmax-NG displayed a much higher correction rate without introducing indels. DNA and RNA off-target analysis did not detect off-target editing in treated embryos and founder mice. In utero injection of adeno-associated virus 9 (AAV9) encoding the ABEmax-NG also resulted in around 25.3% correction of the pathogenic mutation and reduced of mutant RNA, thereby indicating ABEmax-NG has the potential to correct the HCM mutation in vivo. Conclusions: We developed an ABEmax-NG system, which efficiently corrected a pathogenic Myh6 HCM mutation in mouse embryos without off target lesions, thus safely eliminating HCM in derived mice and their progeny.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Efficient Gene Editing in Adult Mouse Livers Via Adenoviral Delivery of CRISPR/Cas9.

Ranran Cheng,Jin Peng,Yonghong Yan,Peili Cao,Jiewei Wang,Chen Qiu,Lichun Tang,Di Liu,Li Tang,Jianping Jin,Xingxu Huang,Fuchu He,Pumin Zhang

DOI: https://doi.org/10.1016/j.febslet.2014.09.008

2014-01-01

FEBS Letters

Abstract:We developed an adenovirus-based CRISPR/Cas9 system for gene editing in vivo. In the liver, we demonstrated that the system could reach the level of tissue-specific gene knockout, resulting in phenotypic changes. Given the wide spectrum of cell types susceptible to adenoviral infection, and the fact that adenoviral genome rarely integrates into its host cell genome, we believe the adenovirus-based CRISPR/Cas9 system will find applications in a variety of experimental settings.
Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Shuming Yin,Lie Ma,Tingting Shao,Mei Zhang,Yuting Guan,Liren Wang,Yaqiang Hu,Xi Chen,Honghui Han,Nan Shen,Wenjuan Qiu,Hongquan Geng,Yongguo Yu,Shichang Li,Weishi Yu,Mingyao Liu,Dali Li

DOI: https://doi.org/10.1007/s11427-020-1744-6

2020-08-17

Science China Life Sciences

Abstract:Genome editing through adeno-associated viral (AAV) vectors is a promising gene therapy strategy for various diseases, especially genetic disorders. However, homologous recombination (HR) efficiency is extremely low in adult animal models. We assumed that increasing AAV transduction efficiency could increase genome editing activity, especially HR efficiency, for in vivo gene therapy. Firstly, a mouse phenylketonuria (PKU) model carrying a pathogenic R408W mutation in phenylalanine hydroxylase (Pah) was generated. Through co-delivery of the general AAV receptor (AAVR), we found that AAVR could dramatically increase AAV transduction efficiency in vitro and in vivo. Furthermore, co-delivery of SaCas9/sgRNA/donor templates with AAVR via AAV8 vectors increased indel rate over 2-fold and HR rate over 15-fold for the correction of the single mutation in PahR408W mice. Moreover, AAVR co-injection successfully increased the site-specific insertion rate of a 1.4 kb Pah cDNA by 11-fold, bringing the HR rate up to 7.3% without detectable global off-target effects. Insertion of Pah cDNA significantly decreased the Phe level and ameliorated PKU symptoms. This study demonstrates a novel strategy to dramatically increase AAV transduction which substantially enhanced in vivo genome editing efficiency in adult animal models, showing clinical potential for both conventional and genome editing-based gene therapy.

biology
Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR–Cas platform

K. Yoshimi,T. Kaneko,B. Voigt,T. Mashimo

DOI: https://doi.org/10.1038/ncomms5240

IF: 16.6

2014-06-26

Nature Communications

Abstract:The bacterial CRISPR/Cas system has proven to be an efficient gene-targeting tool in various organisms. Here we employ CRISPR/Cas for accurate and efficient genome editing in rats. The synthetic chimeric guide RNAs (gRNAs) discriminate a single-nucleotide polymorphism (SNP) difference in rat embryonic fibroblasts, allowing allele-specific genome editing of the dominant phenotype in (F344 × DA)F1 hybrid embryos. Interestingly, the targeted allele, initially assessed by the allele-specific gRNA, is repaired by an interallelic gene conversion between homologous chromosomes. Using single-stranded oligodeoxynucleotides, we recover three recessive phenotypes: the albino phenotype by SNP exchange; the non-agouti phenotype by integration of a 19-bp DNA fragment; and the hooded phenotype by eliminating a 7,098-bp insertional DNA fragment, evolutionary-derived from an endogenous retrovirus. Successful in vivo application of the CRISPR/Cas system confirms its importance as a genetic engineering tool for creating animal models of human diseases and its potential use in gene therapy.

multidisciplinary sciences
A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9

Kelli J. Carroll,Catherine A. Makarewich,John McAnally,Douglas M. Anderson,Lorena Zentilin,Ning Liu,Mauro Giacca,Rhonda Bassel-Duby,Eric N. Olson

DOI: https://doi.org/10.1073/pnas.1523918113

IF: 11.1

2015-12-30

Proceedings of the National Academy of Sciences

Abstract:Significance The recent development of the clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas)9 system has greatly simplified the process of genomic editing. However, it has remained difficult to induce mutations in postnatal animals due to delivery challenges of the CRISPR/Cas9 components. Here, we report the generation of a transgenic mouse line that expresses Cas9 exclusively in cardiomyocytes. By using Adeno-Associated Virus 9 to deliver single-guide RNA (sgRNA) this method can rapidly induce genomic insertions and deletions in the heart. As proof of concept, administration of sgRNA against the Myh6 gene induced Myh6 editing, resulting in cardiomyopathy and heart failure in the cardiac-specific Cas9 mouse. This transgenic mouse model offers a valuable tool for cardiovascular research, as a straightforward strategy to edit genes of interest in the heart.
Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

Kun Zhang,Ping Wan,Liren Wang,Zhen Wang,Fangzhi Tan,Jie Li,Xiaolong Ma,Jin Cen,Xiang Yuan,Yang Liu,Zhen Sun,Xi Cheng,Yuanhua Liu,Xuhao Liu,Jiazhi Hu,Guisheng Zhong,Dali Li,Qiang Xia,Lijian Hui

DOI: https://doi.org/10.1016/j.stem.2024.04.022

IF: 23.9

2024-08-01

Cell Stem Cell

Abstract:Cell-based ex vivo gene therapy in solid organs, especially the liver, has proven technically challenging. Here, we report a feasible strategy for the clinical application of hepatocyte therapy. We first generated high-quality autologous hepatocytes through the large-scale expansion of patient-derived hepatocytes. Moreover, the proliferating patient-derived hepatocytes, together with the AAV2.7m8 variant identified through screening, enabled CRISPR-Cas9-mediated targeted integration efficiently, achieving functional correction of pathogenic mutations in FAH or OTC. Importantly, these edited hepatocytes repopulated the injured mouse liver at high repopulation levels and underwent maturation, successfully treating mice with tyrosinemia following transplantation. Our study combines ex vivo large-scale cell expansion and gene editing in patient-derived transplantable hepatocytes, which holds potential for treating human liver diseases.

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1

CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1

CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency

Development and application of CRISPR/Cas9 technologies in genomic editing.

In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Efficient Gene Editing in Adult Mouse Livers Via Adenoviral Delivery of CRISPR/Cas9.

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR–Cas platform

A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases